Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Galmed Pharmaceuticals Ltd. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q4 2021
- Shares held
- 2.81M
- −1.06M (−27.4%) vs. Q4 2021
- Total value
- $4.47M
- −$2.58M (−36.6%) vs. Q4 2021
- New holders
- 4
- 2 more added
- Sold out
- 5
- 4 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EOCN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $85.9K |
| Q1 2026 | 16 | $71.2K |
| Q4 2025 | 17 | $166.4K |
| Q3 2025 | 14 | $102.0K |
| Q2 2025 | 15 | $140.2K |
| Q1 2025 | 13 | $80.4K |
| Q4 2024 | 12 | $142.8K |
| Q3 2024 | 10 | $38.3K |
| Q2 2024 | 13 | $112.9K |
| Q1 2024 | 13 | $57.6K |
| Q4 2023 | 14 | $248.8K |
| Q3 2023 | 17 | $428.2K |
| Q2 2023 | 12 | $419.1K |
| Q1 2023 | 21 | $878.3K |
| Q4 2022 | 22 | $1.21M |
| Q3 2022 | 25 | $803.6K |
| Q2 2022 | 22 | $1.70M |
| Q1 2022 | 23 | $4.47M |
| Q4 2021 | 24 | $7.05M |
| Q3 2021 | 26 | $11.8M |
| Q2 2021 | 25 | $14.6M |
| Q1 2021 | 30 | $19.4M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Galmed Pharmaceuticals Ltd.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Simplex Trading, LLC | 1,142 | $1.00K | 0.00% | −2,818−71.2% | Reduced |
| Bourgeon Capital Management LLC | 500 | $1.00K | 0.00% | 00.0% | Unchanged |
| McCarthy Asset Management, Inc. | 700 | $1.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 745 | $1.00K | 0.00% | +745 | New |
| Citigroup Inc | 650 | $1.00K | 0.00% | +650 | New |
| PYA Waltman Capital, LLC | 1,000 | $2.00K | 0.00% | 00.0% | Unchanged |
| TD Waterhouse Canada Inc. | 1,000 | $2.03K | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 2,500 | $3.98K | 0.00% | 00.0% | Unchanged |
| TSFG, LLC | 3,000 | $5.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 6,330 | $10.0K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 7,138 | $11.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 9,116 | $14.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 10,745 | $17.0K | 0.00% | −42,494−79.8% | Reduced |
| Brave Asset Management Inc | 11,470 | $18.0K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 12,588 | $20.0K | 0.00% | +12,588 | New |
| Cambridge Investment Research Advisors, Inc. | 26,115 | $42.0K | 0.00% | +26,115 | New |
| Geode Capital Management, LLC | 27,177 | $43.0K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Services Advisors, Inc. | 63,310 | $101.0K | 0.00% | +38,856+158.9% | Added |
| Morgan Stanley | 165,300 | $263.0K | 0.00% | +4,500+2.8% | Added |
| P.A.W. Capital Corp | 200,000 | $318.0K | 0.33% | 00.0% | Unchanged |
| Raymond James & Associates | 202,940 | $323.0K | 0.00% | −600−0.3% | Reduced |
| Nantahala Capital Management, LLC | 258,957 | $412.0K | 0.03% | −38,990−13.1% | Reduced |
| BVF Inc | 1,799,694 | $2.86M | 0.11% | 00.0% | Unchanged |
| Ibex Investors LLC | 0 | $0 | 0.00% | −874,144−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −133,827−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −35,973−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −11,500−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −6,356−100.0% | Sold out |